You Deserve to be Safer

Mark Stanfield’s Story, Oncology Pharmacist

Watch Mark Stanfield’s Story

You Protect Patients, We Protect You

EQUASHIELD® is dedicated to protecting nurses and pharmacists from hazardous drug exposure by developing automated compounding solutions and closed system transfer devices.

85%

Oncology Healthcare Workers
85% tested positive for biomarkers of exposure to hazardous drugs in urine analysis 1

94%

Oncology Healthcare Workers
had a 94% increased risk of spontaneous abortion 2

350%

Oncology Healthcare Workers
had a 350% increased risk of spontaneous abortion among women who previously had a miscarriage or abortion 2

400%

Physicians who routinely handle antineoplastic drugs had a 400% increase in risk for developing leukemia, lymphatic, and hematopoietic cancers 3

20%

Oncology Healthcare Workers
handling anticancer drugs
had a 20% increase in chromosomal abnormality 4

100%

Oncology Pharmacists had a 100% increase in mortality from myeloid leukemia 4

Even Minimal Exposure to Hazardous Drugs is Dangerous

Hazardous Drugs are classified into categories of Carcinogens, Mutagens and Reprotoxic hazards, each with various risks.5

Long Term

white cancer icon

Cancer

genetic and developmental issues

Genetic and Developmental Issues

white cancer icon

Cancer

reprotoxic issues white icon

Reprotoxic
Issues

damage to internal organs white icon

Damage to Internal Organs

white cancer icon

Cancer

Acute

hair loss white icon

Hair Loss

infection white icon

Infection

taste disturbances white icon

Taste
Disturbances

respiratory disease white icon

Respiratory
Disease

reproductive issues white icon

Reproductive
Issues

headaches white icon

Headaches

EQUASHIELD® Leads the U.S. CSTD Market

Ranked as the #1 most utilized CSTD in U.S. pharmacies for the 7th year in a row6

Safer Design

Every element of EQUASHIELD products is designed to be safer

Simpler Design

Simplifies safety with ergonomic and easy to use components

Safety in Automation

Reduces human error, protects healthcare teams from exposure risks, and improves patient safety

Your Safety is Our Priority

At EQUASHIELD®, we prioritize safety and operational excellence in the healthcare field. Our solutions are engineered to prevent errors, enhance nurse, pharmacist, and patient safety, and streamline workflows—all with cutting-edge technology and user centered design.

Not All CSTD are Created Equal

CSTD design affects its ability to be safe and effective

Luer vs. Membrane

Membrane based systems are typically better at leakage prevention than Luer based CSTDs. Testing data consistently highlights EQUASHIELD® as a top performer among membrane-based solutions, effectively preventing microbial ingress.7

Filter vs. Mechanical

Filter based technologies are not mechanically closed, therefore they are not air tight. Mechanical based technologies are designed to ensure an airtight and leak-proof seal through robust physical barriers.

Open Back vs. Closed Back

A closed-back design provides significant safety benefits, including effective containment of vapors and prevention of their release.8 It also safeguards the syringe plunger and barrel from contamination. EQUASHIELD® is the only solution on the market featuring a closed-back design.

Engineered for Maximal Safety

EQUASHIELD® Syringe Units maintain a closed pressure equalization that prevents the escape of vapors and aerosols during compounding and administration. A unique dual-needle, air-to-liquid exchange system, combined with a closed-back sterile air chamber behind the syringe, ensures that pressure is equalized  throughout the hazardous drug handling process.

EQUASHIELD®’s Vial Adaptor firmly snaps onto a standard vial with a unique mechanism that prevents angled or non-centered spiking. The vial adaptor provides a safe and contamination-free vial access port for the Syringe Unit. The vial adaptor’s elastomeric membrane serves as a microbial barrier preventing microbial ingress, while remaining drug residue-free for up to 10 repeated connections in 7 days.

EQUASHIELD’s Spike Adaptors are designed to seamlessly connect standard IV bags to tubing sets, ensuring the safe transfer of hazardous drugs. Engineered with precision, they empower healthcare professionals to compound and administer medications with confidence and ease.

EQUASHIELD® Female Connectors convert standard luer lock ports into a leak-free closed system, ensuring safe and residue-free handling of hazardous drugs. Designed for secure connections and disconnections, they prioritize safety and reliability.

EQUASHIELD® Luer Lock Adaptors ensure a secure connection to patient lines, enabling safe injections with the EQUASHIELD® Syringe Unit or controlled infusions using a female connector. Compatible with any standard luer lock access port, these adaptors are meticulously designed to provide safe, reliable, and efficient administration of hazardous drugs.

Engineered for Maximal Safety

EQUASHIELD® Syringe Units maintain a closed pressure equalization that prevents the escape of vapors and aerosols during compounding and administration. A unique dual-needle, air-to-liquid exchange system, combined with a closed-back sterile air chamber behind the syringe, ensures that pressure is equalized  throughout the hazardous drug handling process.

EQUASHIELD®’s Vial Adaptor firmly snaps onto a standard vial with a unique mechanism that prevents angled or non-centered spiking. The vial adaptor provides a safe and contamination-free vial access port for the Syringe Unit. The vial adaptor’s elastomeric membrane serves as a microbial barrier preventing microbial ingress, while remaining drug residue-free for up to 10 repeated connections in 7 days.

EQUASHIELD’s Spike Adaptors are designed to seamlessly connect standard IV bags to tubing sets, ensuring the safe transfer of hazardous drugs. Engineered with precision, they empower healthcare professionals to compound and administer medications with confidence and ease.

EQUASHIELD® Female Connectors convert standard luer lock ports into a leak-free closed system, ensuring safe and residue-free handling of hazardous drugs. Designed for secure connections and disconnections, they prioritize safety and reliability.

EQUASHIELD® Luer Lock Adaptors ensure a secure connection to patient lines, enabling safe injections with the EQUASHIELD® Syringe Unit or controlled infusions using a female connector. Compatible with any standard luer lock access port, these adaptors are meticulously designed to provide safe, reliable, and efficient administration of hazardous drugs.

What Happens in EQUASHIELD®
Stays in EQUASHIELD®

Our patented closed back design is leakproof and airtight

EQUASHIELD® covers more routes of exposure than alternative systems. Backed by a continually growing library of peer-reviewed and independent clinical studies, our solution ensures leakproof performance, microbial protection, vapor containment, and minimizes surface contamination.

Clinically Backed to be Safer

Safety Shouldn’t be Complicated

EQUASHIELD® CSTD design makes safety simple

/01

Ergonomic design

Ergonomically designed with push on connections vs twist connections. This minimizes repetitive motion injuries (RSIs), reducing the risk of joint pain and carpal tunnel syndrome.

/02

Fail proof connections with red to red markings

Intuitive red markings serve as an alignment indicator, ensuring accurate and secure connections every time.

/03

Pre-assembled components

Pre-assembled Syringe Units and connectors save time and effort. The connector is securely bonded to the Syringe Unit and locking connectors, featuring a needle- free design to prevent accidental needle sticks and disconnects.

/04

No external mechanisms required

EQUASHIELD®’s innovative design streamlines the compounding process by eliminating the need for balloons or external mechanisms required by other systems.

/05

Fastest CSTD to compound and administer

EQUASHIELD® is faster and more efficient to use- requiring the fewest steps to compound, and the lowest average time for administering- the fewest of tested CSTD competitors. With a compounding time saving benefit of approximately 1 min per product, EQUASHIELD consistently outperforms competitors in this category.9,10,11
CSTD EQUASHIELD fully loaded

/06

Full volume use

Standard syringes should only be filled to three-quarters of their capacity when handling hazardous drugs to prevent plunger displacement. EQUASHIELD® Syringe Units are FDA cleared for full volume usage. Benefit from cost savings, reduced strain, time savings, and waste reduction.12

The Future of Safety in Automation

Mundus Mini HD is safer, faster, and effortlessly integrates with your team. By automating manual compounding processes, it significantly reduces the risk of human error. Let Mundus Mini HD handle the repetitive tasks, so your team can focus on what matters most.

What Our Customers Say About Us

Our Mission is to Ensure Your Safety

The EQUASHIELD® Clinical Team consists of certified pharmacy technicians and registered nurses. We offer premium support to ensure your success at every step along the way.  With decades of clinical experience and advanced certifications in sterile compounding and oncology nursing, we understand your needs and speak your language in order to ensure seamless integration of our CSTD and automated compounding solutions.

References:

  1. Wick C, Slawson MH, Jorgenson JA, Tyler LS, et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003;60:2314–2320.
  2. Lawson CC, Rocheleau CM, Whelan EA, et al. Occupational exposures among nurses and risk of spontaneous abortions. Am J Obstet Gynecol. 2012;206:e1–e8.
  3. M.A. McDiarmid, M.S. Oliver, T.S. Roth, B. Rogers, C.P. Escalante, Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs, J. Occup. Environ. Med. 52 (2010) 1028–1034.
  4. S.A. Petralia, M. Dosemeci, E.E. Adams, S.H. Zahm, Cancer mortality among women employed in health care occupations in 24 U.S. states, 1984–1993, Am. J. Ind. Med. 36 (1999) 159–165
  5. National Institute for Occupational Safety and Health (NIOSH). (2004). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings (DHHS (NIOSH) Publication Number 2004−165). Retrieved from https://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf
  6. Pharmacy Purchasing and Products. “State of Pharmacy Compounding,” Volume 22, Number 4, page 60, April 2025 https://www.pppmag.com/digitalmag/Main.php?MagNo=403&PageNo=1#page/62.
  7. Connector Integrity Testing to Assess the Efficacy of Multiple Closed System Transfer Devices – University of North Carolina; Shawn O. Streeter¹, Charlotte M. Forshay¹, Stephanie A. Salch¹, Stephen F. Eckel, PharmD, MHA, BCPS¹,², North Carolina, United States, 2016. https://www.equashield.com/clinical-studies/connector-integrity-testing-to-assess-the-efficacy-of-multiple-closed-system-transfer-devices/
  8. Forshay, M., Streeter, S. O., Salch, S. A., & Eckel, S. F. (2018). Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs. University of North Carolina, Charlotte.  https://www.equashield.com/clinical-studies/application-of-the-2015-proposed-niosh-vapor-containment-performance-protocol-for-closed-system-transfer-devices-used-during-pharmacy-compounding-and-administration-of-hazardous-drugs/
  9. Berdi, F. (2015). Comparing The Efficiency of Closed System Transfer Devices for Compounding Pharmacy Practice & Products. (https://www.equashield.com/clinical-studies/comparing-the-efficiency-of-closed-system-transfer-devices-for-compounding/)
  10. Kicenuik, K., Northrup, N., Dawson, A., Locke, J., Villamil, J. A., Chretin, J., Sfiligoi, G., Clifford, C., Rosenberg, M., Hamilton, T., Regan, R., ParsonsDoherty, M., Mallett, C., Philibert, J., Impellizeri, J., & Hofmeister, E. (2015). Treatment Time, Ease of Use, and Cost Associated With the Use of Equashield™, PhaSeal®, or No Closed System Transfer Device for Administration of Cancer Chemotherapy to a Dog Model. University of Georgia, USA. Retrieved from https://www.equashield.com/clinical-studies/equashield-phaseal-no-cstd-for-administration-of-cancer-chemotherapy-to-dog-model/
  11. Smith, E.K. (2024). Comparison of closed-system transfer devices to compound cytotoxic medicines in a hospital pharmacy compounding unit. Journal of Pharmacy Practice and Research. First published: 22 December 2024. https://doi.org/10.1002/jppr.1954.
  12. FDA Clearance of EQUASHIELD® Syringe Unit for Full Volume Use, EQUASHIELD, October 2023, https://www.equashield.com/articles/fda-clearance-of-equashield-syringe-unit-for-full-volume-use/